Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| iRhythm Holdings, Inc.IRTC · Entity 1499 | Director | May 27, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
iRhythm Holdings, Inc.
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,171 |
Reported balance
After 2026-05-27 transaction · row 1
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 1,573 · Balance 7,171 F1: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of IRTC Common Stock. The vesting occurs on the earlier of (i) one year after grant or the (ii) the date of the company's next annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of IRTC Common Stock. The vesting occurs on the earlier of (i) one year after grant or the (ii) the date of the company's next annual meeting.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ABBOTT LABORATORIES
Report date February 28, 2020 · Filed March 03, 2020
Section 16 reporting ended · disclosed 2020-03-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 114,099 |
Reported balance
After 2020-02-28 transaction · row 1
1 source rowRow 1 · 2020-02-28 · Tax withholding · Disposed 14,318 · Balance 114,099 |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 2,248 |
Reported balance
Holding disclosure · report date 2020-02-28 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,248 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of February 28, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of February 28, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 27, 2026 Filed May 29, 2026 20:01 UTC | iRhythm Holdings, Inc. IRTC · Entity 1499 | GrantCommon Stock | 1,573 | $0.00 | $0.00 |
DisclosureSEC source: 0001643528-26-000003 · wk-form4_1780084869.xml · nonDerivative · entry 1 YOOR BRIAN B · CIK 0001643528 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,171 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of IRTC Common Stock. The vesting occurs on the earlier of (i) one year after grant or the (ii) the date of the company's next annual meeting. Read SEC document |
| May 28, 2025 Filed May 29, 2025 20:06 UTC | iRhythm Holdings, Inc. IRTC · Entity 1499 | GrantCommon Stock | 1,358 | $0.00 | $0.00 |
DisclosureSEC source: 0001388658-25-000138 · wk-form4_1748549182.xml · nonDerivative · entry 1 YOOR BRIAN B · CIK 0001643528 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,598 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of IRTC Common Stock. The vesting occurs on the earlier of (i) one year after grant or the (ii) the date of the company's next annual meeting. Read SEC document |
| May 29, 2024 Filed Jun 3, 2024 22:48 UTC | iRhythm Holdings, Inc. IRTC · Entity 1499 | GrantCommon Stock | 1,841 | $0.00 | $0.00 |
DisclosureSEC source: 0001388658-24-000121 · wk-form4_1717454913.xml · nonDerivative · entry 1 YOOR BRIAN B · CIK 0001643528 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,240 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of IRTC Common Stock. The vesting occurs on the earlier of (i) one year after grant or the (ii) the date of the company's next annual meeting. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:35 UTC | iRhythm Holdings, Inc. IRTC · Entity 1499 | GrantCommon Stock | 2,399 | $0.00 | $0.00 |
DisclosureSEC source: 0001388658-23-000085 · wk-form4_1685997286.xml · nonDerivative · entry 1 YOOR BRIAN B · CIK 0001643528 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,399 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs vest over a three-year period on June 1, 2024, and each one-year anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 14,318 | $79.19 | $1,133,842.42 |
DisclosureSEC source: 0001179110-20-002892 · edgar.xml · nonDerivative · entry 1 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,099 Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:19 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 85,562 | $0.00 Strike: $87.72 | $0.00 |
DisclosureSEC source: 0001179110-20-002269 · edgar.xml · derivative · entry 3 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,562 Underlying: Common shares · 85,562 shares Expires 2030-02-20 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 28,520 on February 21, 2021, 28,521 on February 21, 2022, and 28,521 on February 21, 2023. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:19 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 14,036 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002269 · edgar.xml · nonDerivative · entry 1 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,417 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 22:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 82,321 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001179110-20-000889 · edgar.xml · derivative · entry 12 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,642 Underlying: Common shares · 82,321 shares Expires 2028-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 22:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 91,121 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001179110-20-000889 · edgar.xml · derivative · entry 11 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,561 Underlying: Common shares · 91,121 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 22:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 213,470 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-20-000889 · edgar.xml · derivative · entry 10 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 213,470 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 22:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 81,709 | $0.00 Strike: $48.90 | $0.00 |
DisclosureSEC source: 0001179110-20-000889 · edgar.xml · derivative · entry 9 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 81,709 shares Expires 2025-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 22:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 41,229 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001179110-20-000889 · edgar.xml · derivative · entry 8 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 41,229 shares Expires 2025-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 22:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 509,850 | $89.73 | $45,747,208.98 |
DisclosureSEC source: 0001179110-20-000889 · edgar.xml · nonDerivative · entry 6 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,381 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.57 to $89.87, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 22:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 82,321 | $59.94 | $4,934,320.74 |
DisclosureSEC source: 0001179110-20-000889 · edgar.xml · nonDerivative · entry 5 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 624,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 22:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 91,121 | $44.40 | $4,045,772.40 |
DisclosureSEC source: 0001179110-20-000889 · edgar.xml · nonDerivative · entry 4 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 541,910 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 22:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 213,470 | $38.40 | $8,197,248.00 |
DisclosureSEC source: 0001179110-20-000889 · edgar.xml · nonDerivative · entry 3 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 22:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 81,709 | $48.90 | $3,995,570.10 |
DisclosureSEC source: 0001179110-20-000889 · edgar.xml · nonDerivative · entry 2 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,319 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 22:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 41,229 | $47.00 | $1,937,763.00 |
DisclosureSEC source: 0001179110-20-000889 · edgar.xml · nonDerivative · entry 1 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2019 Filed Aug 9, 2019 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 32,363 | $0.00 Strike: $39.12 | $0.00 |
DisclosureSEC source: 0001179110-19-009357 · edgar.xml · derivative · entry 6 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 32,363 shares Expires 2024-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 08, 2019 Filed Aug 9, 2019 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 11,400 | $0.00 Strike: $34.94 | $0.00 |
DisclosureSEC source: 0001179110-19-009357 · edgar.xml · derivative · entry 5 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 11,400 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 08, 2019 Filed Aug 9, 2019 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 43,763 | $85.77 | $3,753,705.68 |
DisclosureSEC source: 0001179110-19-009357 · edgar.xml · nonDerivative · entry 3 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,381 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.50 to $86.21, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 08, 2019 Filed Aug 9, 2019 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 32,363 | $39.12 | $1,266,040.56 |
DisclosureSEC source: 0001179110-19-009357 · edgar.xml · nonDerivative · entry 2 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,144 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2019 Filed Aug 9, 2019 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 11,400 | $34.94 | $398,316.00 |
DisclosureSEC source: 0001179110-19-009357 · edgar.xml · nonDerivative · entry 1 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,246 | $78.00 | $175,188.00 |
DisclosureSEC source: 0001179110-19-003129 · edgar.xml · nonDerivative · entry 2 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,381 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 22:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 13,127 | $77.23 | $1,013,798.21 |
DisclosureSEC source: 0001179110-19-003129 · edgar.xml · nonDerivative · entry 1 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,627 Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 169,198 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001179110-19-002651 · edgar.xml · derivative · entry 3 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,198 Underlying: Common shares · 169,198 shares Expires 2029-02-21 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 56,399 on February 22, 2020, 56,399 on February 22, 2021, and 56,400 on February 22, 2022. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 32,279 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002651 · edgar.xml · nonDerivative · entry 1 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,754 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,713 | $61.53 | $105,400.89 |
DisclosureSEC source: 0001179110-18-008105 · edgar.xml · nonDerivative · entry 1 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,475 Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 7,379 | $60.55 | $446,798.45 |
DisclosureSEC source: 0001179110-18-003305 · edgar.xml · nonDerivative · entry 1 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,188 Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:19 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 246,963 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001179110-18-002509 · edgar.xml · derivative · entry 3 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,963 Underlying: Common shares · 246,963 shares Expires 2028-02-15 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 82,321 on 02/16/2019, 82,321 on 02/16/2020, and 82,321 on 02/16/2021. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:19 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 44,909 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002509 · edgar.xml · nonDerivative · entry 1 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,567 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 22:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,767 | $45.66 | $80,681.22 |
DisclosureSEC source: 0001179110-17-008471 · edgar.xml · nonDerivative · entry 1 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,658 Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 22:19 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,728 | $45.39 | $78,433.92 |
DisclosureSEC source: 0001179110-17-003683 · edgar.xml · nonDerivative · entry 2 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,425 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:19 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 4,227 | $45.46 | $192,159.42 |
DisclosureSEC source: 0001179110-17-003683 · edgar.xml · nonDerivative · entry 1 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,153 Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 23:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 136,682 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001179110-17-002965 · edgar.xml · derivative · entry 3 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,682 Underlying: Common shares · 136,682 shares Expires 2027-02-16 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 45,561 on 2/17/2018, 45,560 on 2/17/2019, and 45,561 on 2/17/2020. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 23:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 19,763 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002965 · edgar.xml · nonDerivative · entry 1 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,380 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| June 01, 2016 Filed Jun 3, 2016 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 565 | $39.49 | $22,312.42 |
DisclosureSEC source: 0001179110-16-025994 · edgar.xml · nonDerivative · entry 2 YOOR BRIAN B · CIK 0001643528 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,617 Read SEC document |
| June 01, 2016 Filed Jun 3, 2016 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,203 | $39.63 | $47,674.89 |
DisclosureSEC source: 0001179110-16-025994 · edgar.xml · nonDerivative · entry 1 YOOR BRIAN B · CIK 0001643528 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,182 Read SEC document |
| February 29, 2016 Filed Mar 3, 2016 00:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 700 | $39.13 | $27,387.50 |
DisclosureSEC source: 0001179110-16-020731 · edgar.xml · nonDerivative · entry 3 YOOR BRIAN B · CIK 0001643528 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,385 Read SEC document |
| February 29, 2016 Filed Mar 3, 2016 00:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 165 | $39.12 | $6,455.18 |
DisclosureSEC source: 0001179110-16-020731 · edgar.xml · nonDerivative · entry 2 YOOR BRIAN B · CIK 0001643528 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,085 Read SEC document |
| February 29, 2016 Filed Mar 3, 2016 00:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,840 | $39.52 | $72,716.80 |
DisclosureSEC source: 0001179110-16-020731 · edgar.xml · nonDerivative · entry 1 YOOR BRIAN B · CIK 0001643528 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,250 Read SEC document |
| February 19, 2016 Filed Feb 23, 2016 23:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 213,470 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-16-019929 · edgar.xml · derivative · entry 3 YOOR BRIAN B · CIK 0001643528 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,470 Underlying: Common shares · 213,470 shares Expires 2026-02-18 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 71,157 on 02/19/2017, 71,156 on 02/19/2018, and 71,157 on 02/19/2019. Read SEC document |
| February 19, 2016 Filed Feb 23, 2016 23:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 24,348 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-019929 · edgar.xml · nonDerivative · entry 1 YOOR BRIAN B · CIK 0001643528 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,090 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| June 01, 2015 Filed Jun 3, 2015 21:38 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 81,709 | $0.00 Strike: $48.90 | $0.00 |
DisclosureSEC source: 0001179110-15-009074 · edgar.xml · derivative · entry 3 YOOR BRIAN B · CIK 0001643528 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,709 Underlying: Common shares · 81,709 shares Expires 2025-05-31 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 27,237 on 6/1/2016, 27,236 on 6/1/2017, and 27,236 on 6/1/2018. Read SEC document |
| June 01, 2015 Filed Jun 3, 2015 21:38 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 11,596 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-009074 · edgar.xml · nonDerivative · entry 1 YOOR BRIAN B · CIK 0001643528 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,742 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.